Abstract:BackgroundBreast cancer is a highly heterogeneous disease resulting in diverse clinical behaviours and therapeutic responses. DNA methylation is a major epigenetic alteration that is commonly perturbed in cancers. The aim of this study is to characterize the relationship between DNA methylation and aberrant gene expression in breast cancer.MethodsWe analysed DNA methylation and gene expression profiles from breast cancer tissue and matched normal tissue in The Cancer Genome Atlas (TCGA). Genome-wide differential methylation analysis and methylation-gene expression correlation was performed. Gene expression changes were subsequently validated in the METABRIC dataset. The Oncoscore tool was used to identify genes that had previously been associated with cancer in the literature. A subset of genes that had not previously been studied in cancer was chosen for further analysis.ResultsWe identified 368 CpGs that were differentially methylated between tumor and normal breast tissue (∆β > 0.4). Hypermethylated CpGs were overrepresented in tumor tissue and were found predominantly (56%) in upstream promoter regions. Conversely, hypomethylated CpG sites were found primarily in the gene body (66%). Expression analysis revealed that 209 of the differentially-methylated CpGs were located in 169 genes that were differently expressed between normal and breast tumor tissue. Methylation-expression correlations were predominantly negative (70%) for promoter CpG sites and positive (74%) for gene body CpG sites. Among these differentially-methylated and differentially-expressed genes, we identified 7 that had not previously been studied in any form of cancer. Three of these, TDRD10, PRAC2 and TMEM132C, contained CpG sites that showed diagnostic and prognostic value in breast cancer, particularly in estrogen-receptor (ER)-positive samples. A pan-cancer analysis confirmed differential expression of these genes together with diagnostic and prognostic value of their respective CpG sites in multiple cancer types.ConclusionWe have identified 368 DNA methylation changes that characterize breast cancer tumor tissue, of which 209 are associated with genes that are differentially-expressed in the same samples. Novel DNA methylation markers were identified, of which cg12374721 (PRAC2), cg18081940 (TDRD10) and cg04475027 (TMEM132C) show promise as diagnostic and prognostic markers in breast cancer as well as other cancer types.

Discovered Key CpG Sites by Analyzing DNA Methylation and Gene Expression in Breast Cancer Samples

Discovering the Key Genes and Important DNA Methylation Regions in Breast Cancer

Relationship Between DNA Methylation in Key Region and the Differential Expressions of Genes in Human Breast Tumor Tissue

Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers

Identification of Methylation Markers and Differentially Expressed Genes with Prognostic Value in Breast Cancer.

CpG Methylation Signature Predicts Prognosis in Breast Cancer.

DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers.

Identification of cancer DNA methylation regulatory sites

Effects of Differentially Methylated CpG Sites in Enhancer and Promoter Regions on the Chromatin Structures of Target LncRNAs in Breast Cancer

Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients

Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers

Potential Biomarkers: the Hypomethylation of Cg18949415 and Cg22193385 Sites in Colon Adenocarcinoma

Identification of Aberrantly Methylated Differentially Expressed Genes in Breast Cancer by Integrated Bioinformatics Analysis

The Prediction of Tumor and Normal Tissues Based on the DNA Methylation Values of Ten Key Sites.

DNA methylation profiles capturing breast cancer heterogeneity

A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer.

Aberrant Promoter Methylation of Cancer-Related Genes in Human Breast Cancer

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer

DNA Methylation Based Molecular Subtypes Predict Prognosis in Breast Cancer Patients

Determination of Genetic and Epigenetic Modifications-Related Prognostic Biomarkers of Breast Cancer: Genome High-Throughput Data Analysis

Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis